[Effect of one-year treatment with low simvastatin doses on lipids and Lp(a) in patients with significant hypercholesterolemia].
The aim of study was to evaluate efficacy and safety of one-year therapy with simvastatin in relative low doses (5-20 mg/d). The examination was performed in the group of 55 patients with significant hypercholesterolemia (Fredrickson's type II). During one-year treatment with simvastatin there were observed the mean decrease of total cholesterol (TC) by 26%, LDL-C by 37%, and LDL-C/HDL-C rate by 38%. The normalization of cholesterolemia (TC < 200 and LDL-C < 130 mg/dL) was observed in 53% of patients (group A-75%, and group B-39%). Effective doses of simvastatin varied from 5 to 20 mg/d. Lp(a) decreased statistically significantly only in the group of patients with extensively elevated Lp(a): from 121.1 +/- 46.2 mg/dL before the treatment to 95.3 +/- 31.3 mg/dL after them. Hepatotoxic effects were not observed and antipyrine kinetics did not change during one-year treatment with simvastatin.
Adamska-Dyniewska
H
H
Zakład Farmakologii Klinicznej z Oddziałem Chorób Wewnetrznych IMW WAM w Lodzi.
Chojnowska-Jezierska
J
J
D000328:Adult; D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019821:Simvastatin / Q000008:administration & dosage*; D016896:Treatment Outcome
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D017270:Lipoprotein(a); D019821:Simvastatin
Wpływ rocznego leczenia niewielkimi dawkami simwastatyny na lipidogram i Lp(a) u chorych z nasilona hipercholesterolemia.